Platforms

Home
Platforms

Our Technology Platform

Ace Therapeutics possesses a comprehensive suite of key technology platforms tailored for psychiatric drug discovery and development. Our capabilities encompass the behavioral testing platform, neuroimaging platform, electrophysiology platform, autoradiography platform, molecular biology & biochemistry platform, histological analysis platform, optogenetics platform, chemogenetics platform, and others. Together, these platforms enable robust preclinical research and support the efficient translation of innovative therapies for psychiatric disorders.

Behavioral Neuroscience Platform

Ace Therapeutics' neurobehavioral platform offers comprehensive, standardized testing to evaluate rodent behaviors in anxiety, depression, motor function, cognition, and other domains. We utilize validated experimental paradigms and automated tracking systems to provide reliable data for psychiatric disease research and drug development.

Neuroimaging Platform

We leverage advanced neuroimaging technologies to provide critical support for the discovery and development of psychiatric drugs. We apply structural and functional neuroimaging approaches to help identify therapeutic targets and assess drug-target engagement in the brain.

Electrophysiology Platform

Leveraging deep electrophysiology expertise, Ace Therapeutics provides comprehensive functional data for psychiatric research. By integrating patch-clamp, EEG, and high-density MEA systems, we capture neural activity from single channels to complex networks.

Autoradiography Platform

Ace Therapeutics' autoradiography Platform enables high-resolution visualization and quantitative analysis of radiolabeled compounds in tissue sections. This platform accurately assesses drug distribution, target binding characteristics, and receptor occupancy in the brain and other tissues.

Molecular Biology & Biochemistry Platform

Ace Therapeutics' molecular biology and biochemistry platform is equipped with a diverse range of analytical instruments, providing efficient and reliable detection services for a variety of molecular indicators in psychiatric drug research and development, from gene to protein level, including qPCR, Western blot, ELISA, and neurotransmitter analysis.

Histological Analysis Platform

Histological analysis platform offers a complete workflow including tissue processing, sectioning, and staining, with capabilities in H&E, immunohistochemistry (IHC), immunofluorescence (IF), and special stains. We provide high-resolution histopathological evaluation of target tissues from neuropsychiatric disease models to support drug safety and mechanism of action studies.

Optogenetics Platform

Using optogenetics, our platform enables millisecond-precise control of neural circuits in freely behaving animals to support mechanistic research and target validation for depression, anxiety, and other psychiatric disorders.

Chemogenetics Platform

Our chemogenetics platform enables reversible activation or inhibition of neuronal activity, providing a powerful tool for dissecting the function of neural circuits associated with psychiatric disorders and validating drug targets.

Important Links

Enter Your Email to Subscribe

Enter your E-mail and receive the latest news from us

Top